BOSTON, Sept. 24, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical
company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the
treatment of aging-related diseases, today announced that company management will present a corporate overview at the 2018 Cantor
Fitzgerald Global Healthcare Conference on Monday, October 1, 2018 at 3:30 p.m. ET in New York, NY.
A live audio webcast of the presentation can be accessed on the Investors section of resTORbio’s website at http://ir.restorbio.com/investors. An archived replay will be available for at least 30 days
following the presentation.
About resTORbio
resTORbio, Inc. is a clinical stage biopharmaceutical company targeting TORC1 and other biological pathways that regulate aging to
develop innovative medicines with the potential to extend healthy lifespan. resTORbio’s lead program is selectively targeting
TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including the
immune, cardiovascular and central nervous systems.
Investor and Media Contact:
Jennifer Robinson
resTORbio, Inc.
857-772-7029
jrobinson@restorbio.com
